SPTX ▲ +0.3% - Seaport Therapeutics, Inc.
$SPTX Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
07-OCT-2026 07:03 AM ET
Share this post
More filings for $SPTX
SPTX - Seaport Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026SPTX - Seaport Therapeutics, Inc. - SEC Filing Update (05-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 5, 2026SPTX SEC Filing Update (05-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 5, 2026
View full $SPTX filing history →💬 Comments
Loading comments…
Leave a comment